Specialty· August 31, 2026 · 36 min read
Generic Erleada (Apalutamide): U.S. Entry, Patents, and Launch Signals
By Ran Chen#Oncology#Generic Entry#Orange Book
Topic
Patent Cliff
Loss of exclusivity, composition-of-matter patent expirations, generic and biosimilar entry timing, and revenue-cliff analysis.
Pipeline· August 19, 2026 · 16 min read
INTerpath-001 Phase 3: Intismeran Autogene and Keytruda's Post-2028 Strategy
By Ran Chen#Pipeline#Clinical Evidence#Pivotal Trials
Specialty· August 15, 2026 · 23 min read
Prostate Cancer Treatment Access Landscape: Xtandi Patent Wall & Generics
By Ran Chen#Oncology#Generic Entry#Orange Book
Specialty· August 14, 2026 · 24 min read
Multiple Myeloma Treatment Access Landscape: Generic Revlimid, Zenbexus, & Darzalex
Approvals· August 12, 2026 · 34 min read
Gilead's BIC/LEN Single-Tablet HIV Regimen: PDUFA, Phase 3, and Access
By Ran Chen#FDA Approval#HIV#Gilead Sciences
Specialty· August 11, 2026 · 17 min read
Myelofibrosis Treatment Access Landscape: Jakafi, Vonjo, & Selinexor
By Ran Chen#Hematology#JAK Inhibitor#Specialty Pharmacy
Specialty· August 9, 2026 · 17 min read
Alopecia Areata Treatment Access (2026): Litfulo, Leqselvi, and Olumiant
Pricing & Access· August 8, 2026 · 14 min read
Novo Nordisk portfolio dossier (Q2 2026): Wegovy, CagriSema & obesity pipeline
By Ran Chen#Novo Nordisk#Semaglutide#Wegovy
Pricing & Access· July 27, 2026 · 18 min read
Multiple Sclerosis Disease-Modifying Therapy Access Landscape (2026)
By Ran Chen#Multiple Sclerosis#Biosimilars#Patent Cliff